Home Healthcare


Omega Healthcare Investors (NYSE:OHI)

Omega Healthcare Investors (NYSE:OHI) a Swan Stock or Not?

Shareholders of Omega Healthcare Investors (NYSE:OHI) has seen their holdings decrease for quite some time. In 2017, the stock decreased 20% and in the past three years, the total price return has been 37.17%. However, if one focus on total return, the investment hasn’t been that bad. Omega Healthcare Investors yields close to 10%,... Read more
Gilead Sciences, Inc. (NASDAQ:GILD)

Gilead Sciences, Inc. (GILD) Blockbuster Pipeline, M&A to Offset HCV Declines

2017 was not a good year for Gilead Sciences, Inc. (NASDAQ:GILD), as the company announced weak sales of core hepatitis C drugs Harvoni, Sovaldi and Epclusa. These drugs are under pressure amid pricing problems and competition. Gilead also recently posted fourth quarter results that were not up to the expectations. Total HCV franchise revenue... Read more
Healthcare Companies

Will Berkshire Hathaway, JPMorgan and Amazon Succeed in Disrupting the Healthcare...

The latest rumour has it that Warren Buffet, Jeff Bezos and Jamie Dimon will team up to disrupt the healthcare sector. They say that healthcare prices and pharmaceutical prices are way too high, and that they share a common goal about helping fellow Americans. However, the main goal is to create an independent health... Read more
Aimmune Therapeutics Inc. (NASDAQ: AIMT)

Aimmune Therapeutics (NASDAQ: AIMT) Betting on Phase 3

Aimmune Therapeutics Inc. (NASDAQ: AIMT), is currently developing therapies for peanut and other food allergies using its Characterized Oral Desensitization Immunotherapy (CODIT) system. The company’s lead biologic candidate for peanut allergies, AR101, completed a Phase 2 study a couple years ago with surprisingly positive resultsThe Phase 2 study, which consisted of 23 patients (both... Read more
UnitedHealth (NYSE:UNH)

UnitedHealth (UNH) Scoops up Davita (DVA) Unit in $4.9 Billion Deal

UnitedHealth Group Inc. (NYSE:UNH), the largest health insurer in the U.S., continued to expand its presence in the health services sector with the acquisition of DaVita Medical Group, the primary and urgent care services unit of kidney dialysis firm DaVita Inc. (NYSE:DVA), for $4.9 billion.  DaVita Medical Group has a network of nearly 300... Read more
AbbVie Inc (NYSE:ABBV)

AbbVie Inc (NYSE:ABBV) Is the Best Pharmaceutical Investment. Here’s Why.

AbbVie Inc(NYSE:ABBV) has proven itself to be one of the best pharmaceutical stocks to own in 2017. The stock is up over 50% year-to-date. AbbVie stock is poised for more growth amid several factors. First, the company is set to launch a Humira biosimilar. The company announced in September that it had settled its... Read more
Johnson & Johnson (NYSE:JNJ)

Johnson​ ​&​ ​Johnson (NYSE:JNJ) – ​a​ ​Defensive​ ​Growth​ ​Opportunity

As the world’s leading manufacturer of health care products, Johnson & Johnson (NYSE:JNJ) operates in nearly 60 countries and sells its product in about 200 countries. Nearly 55% of Johnson & Johnson’s revenue is derived from international markets. Over the past 131 years, the company has diversified its business into three core segments: pharmaceutical,... Read more
Gilead Sciences, Inc. (NASDAQ:GILD)

Gilead Sciences, Inc. (NASDAQ:GILD) Will Skyrocket in 2018 – Here’s Why

Gilead Sciences, Inc. (NASDAQ:GILD) is under pressure amid weaknesses in the HCV business. Gilead’s revenue in the third quarter slumped 13% while net income in the period declined by 18% year-over-year. Thanks to it consistent mergers & acquisitions practice the company has exposure to several other industries. Gilead stock is up over 3% since... Read more

Should You Buy Amgen,Inc. (NASDAQ:AMGN) for Profits in 2018?

Amgen, Inc.(NASDAQ:AMGN) reported better-than-expected third quarter results last month. For full fiscal 2017, the company expects to earn EPS of $12.50-$12.70, versus the consensus of $12.57. Revenue forecast for the full year is $22.7-$23 billion, versus the consensus of $22.87 billion. However, revenue in the third quarter declined by 1% year-over-year. Financial services company... Read more
Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA)

Can Kare Schultz Save Teva Pharmaceutical Industries Ltd (ADR) (TEVA)?

Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) is losing value after the company posted disappointing third quarter results and issued a lower-than-expected forecast. Teva’s third quarter revenue missed the estimates by $10 million. The company is under pressure amid the loss of exclusivity for Copaxone. The specialty segment of Teva Pharmaceutical did show signs of... Read more